Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 2, Pages 319-331
Publisher
Wiley
Online
2013-07-02
DOI
10.1002/ijc.28362
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Latency-Associated Peptide Identifies a Novel CD4+CD25+ Regulatory T Cell Subset with TGF -Mediated Function and Enhanced Suppression of Experimental Autoimmune Encephalomyelitis
- (2014) M.-L. Chen et al. JOURNAL OF IMMUNOLOGY
- Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
- (2012) Roniel Cabrera et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma
- (2012) Hidenari Nagai et al. Clinical & Developmental Immunology
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma
- (2011) Anne Flörcken et al. ANTI-CANCER DRUGS
- Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
- (2011) Antonia Busse et al. EUROPEAN JOURNAL OF CANCER
- Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family
- (2011) Hélène Bour-Jordan et al. IMMUNOLOGICAL REVIEWS
- Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia
- (2011) Shuiying Hu et al. JNCI-Journal of the National Cancer Institute
- Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
- (2011) Mengde Cao et al. LABORATORY INVESTIGATION
- Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
- (2010) Jennifer S. Ko et al. CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
- (2010) Ingrid M.E. Desar et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- (2009) L. Zhang et al. BLOOD
- Costimulatory and coinhibitory receptors in anti-tumor immunity
- (2009) Gregory Driessens et al. IMMUNOLOGICAL REVIEWS
- The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro
- (2009) M. Krusch et al. JOURNAL OF IMMUNOLOGY
- MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
- (2009) R. Houben et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
- (2008) W Zhao et al. LEUKEMIA
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More